Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models

Thumbnail Image
Download
Name

PIIS221112472101247X.pdf

Description
Published version
Size

5.09 MB

Format

Adobe PDF

Checksum (MD5)

7e1c94d8914b6b3dcaae177a3274a1d6

sword-2023-02-03T19:26:14.original.xml (130 B)
Original SWORD entry document
Author(s)
Stockslager, Max A
•
Malinowski, Seth
•
Touat, Mehdi
•
Yoon, Jennifer C
•
Geduldig, Jack
•
Mirza, Mahnoor
•
Kim, Annette S
•
Wen, Patrick Y
•
Chow, Kin-Hoe
•
Ligon, Keith L
more
Date Issued
2021
Journal
Cell Reports
Publisher
Elsevier BV
Citation
Stockslager, Max A, Malinowski, Seth, Touat, Mehdi, Yoon, Jennifer C, Geduldig, Jack et al. 2021. "Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models." Cell Reports, 37 (1).
Version
Final published version
Abstract
Functional precision medicine aims to match individual cancer patients to optimal treatment through ex vivo drug susceptibility testing on patient-derived cells. However, few functional diagnostic assays have been validated against patient outcomes at scale because of limitations of such assays. Here, we describe a high-throughput assay that detects subtle changes in the mass of individual drug-treated cancer cells as a surrogate biomarker for patient treatment response. To validate this approach, we determined ex vivo response to temozolomide in a retrospective cohort of 69 glioblastoma patient-derived neurosphere models with matched patient survival and genomics. Temozolomide-induced changes in cell mass distributions predict patient overall survival similarly to O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and may aid in predictions in gliomas with mismatch-repair variants of unknown significance, where MGMT is not predictive. Our findings suggest cell mass is a promising functional biomarker for cancers and drugs that lack genomic biomarkers.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/147876
DOI of Published Version
https://doi.org/10.1016/J.CELREP.2021.109788
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.